Skip to main content

Development, optimisation and implementation of artificial intelligence methods for real world data analyses in regulatory decision-making and health technology assessment along the product lifecycle

Objective

Real-world evidence derived from real-world data (RWD) has a promising role to inform regulatory decision-making. Based on highly relevant use cases from regulatory practice and across the product lifecycle Real4Reg develops AI-based data-driven methods and tools for the assessment of medicinal products. Findings will inform training activities on good practice examples and will be implemented in existing and emerging guidelines for both health regulatory authorities and health technology assessment (HTA) bodies across Europe. There is urgent need to enable the use and establish the value of the application of RWD across the spectrum of regulatory use cases. The use of RWD is established in regulatory processes such as safety monitoring, but evidentiary value for further use cases, especially in the pre-authorisation and evaluation phase of medicinal products, is rudimentary. The use of RWD in post-authorisation steps is constrained by data variability and by challenges in analysing data from different settings and sources. Thus, the development of new and optimised methods for RWD analyses is essential. Real4Reg addresses the challenges and opportunities of RWD analyses across different health care systems by involving multiple stakeholders to work together in a collaborative approach, also outreaching to already established European initiatives. Our consortium assembles partners with outstanding excellence in the field of RWD analyses, including experts from regulatory agencies/ HTA (BfArM, DKMA, Infarmed), academia (Fraunhofer, UEF, CSC, AU, DZNE) and patient organisations (EUpALS, EIWH). In an advisory board stakeholders provide input and guidance to the project, including patients, industry, payers, HTA bodies and healthcare professionals. The structure and approach of our project facilitates the successful implementation of the effective use of RWD in regulatory decision-making and HTA, and ultimately supports the application of better medicines for patients.

Coordinator

BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE
Net EU contribution
€ 1 495 828,75
Address
Kurt Georg Kiesinger Allee 3
53175 Bonn
Germany

See on map

Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Research Organisations
Other funding
€ 0,00

Participants (9)

ITA-SUOMEN YLIOPISTO
Finland
Net EU contribution
€ 1 255 375,00
Address
Yliopistonranta 1 E
70211 Kuopio

See on map

Region
Manner-Suomi Pohjois- ja Itä-Suomi Pohjois-Savo
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
INFARMED - AUTORIDADE NACIONAL DO MEDICAMENTO E PRODUTOS DA SAUDE IP
Portugal
Net EU contribution
€ 1 061 812,50
Address
Avenida Do Brasil 53
1749 004 Lisboa

See on map

Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 0,00
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany
Net EU contribution
€ 1 349 982,50
Address
Hansastrasse 27c
80686 Munchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Other funding
€ 0,00
LAEGEMIDDELSTYRELSEN
Denmark
Net EU contribution
€ 683 750,00
Address
Axel Heides Gade 1
2300 Kobenhavn S

See on map

Region
Danmark Hovedstaden Byen København
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 0,00
AARHUS UNIVERSITET
Denmark
Net EU contribution
€ 456 610,00
Address
Nordre Ringgade 1
8000 Aarhus C

See on map

Region
Danmark Midtjylland Østjylland
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
CSC-TIETEEN TIETOTEKNIIKAN KESKUS OY
Finland
Net EU contribution
€ 492 160,00
Address
Keilaranta 14
02101 Espoo

See on map

Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Other
Other funding
€ 0,00
DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Germany
Net EU contribution
€ 78 906,25
Address
Venusberg-campus 1/99
53127 Bonn

See on map

Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Research Organisations
Other funding
€ 0,00
EUROPESE VERENIGING VOOR PROFESSIONALS EN PATIENTEN MET ALS
Belgium
Net EU contribution
€ 62 500,00
Address
Vaartkom 17
3000 Leuven

See on map

Region
Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven
Activity type
Other
Other funding
€ 0,00
EUROPEAN INSTITUTE OF WOMEN'S HEALTH COMPANY LIMITED BY GUARANTEE
Ireland
Net EU contribution
€ 62 500,00
Address
Pearse Street 33
2 Dublin

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Northern and Western Border
Activity type
Research Organisations
Other funding
€ 0,00